KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Capital Employed (2018 - 2025)

Esperion Therapeutics' Return on Capital Employed history spans 8 years, with the latest figure at 0.53% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 13.0% year-over-year to 0.53%; the TTM value through Dec 2025 reached 0.53%, down 13.0%, while the annual FY2025 figure was 0.58%, 132.0% down from the prior year.
  • Return on Capital Employed reached 0.53% in Q4 2025 per ESPR's latest filing, down from 8.44% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 8.44% in Q3 2025 to a low of 2.71% in Q4 2023.
  • Average Return on Capital Employed over 5 years is 0.35%, with a median of 0.85% recorded in 2022.
  • Peak YoY movement for Return on Capital Employed: plummeted -176bps in 2023, then surged 834bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.99% in 2021, then increased by 3bps to 0.95% in 2022, then plummeted by -184bps to 2.71% in 2023, then soared by 124bps to 0.66% in 2024, then dropped by -20bps to 0.53% in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Return on Capital Employed are 0.53% (Q4 2025), 8.44% (Q3 2025), and 0.96% (Q2 2025).